Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
Climb Bio (Nasdaq: CLYM) has announced its participation in William Blair's Transforming Autoimmune Diseases by Targeting CD19 event. The company will present and host investor meetings at this conference, which is scheduled for Wednesday, October 16, 2024, in New York, NY.
This event focuses on innovative approaches to treating autoimmune diseases, specifically targeting CD19. Climb Bio's involvement suggests their work aligns with this cutting-edge area of medical research. The conference provides an opportunity for Climb Bio to showcase their developments and engage with investors interested in advancements in autoimmune disease treatments.
Climb Bio (Nasdaq: CLYM) ha annunciato la sua partecipazione all'evento Transforming Autoimmune Diseases by Targeting CD19 di William Blair. L'azienda presenterà e ospiterà incontri con investitori durante questa conferenza, che si terrà mercoledì 16 ottobre 2024, a New York, NY.
Questo evento si concentra su approcci innovativi per il trattamento delle malattie autoimmuni, mirando specificamente al CD19. Il coinvolgimento di Climb Bio suggerisce che il loro lavoro è in linea con questo ambito all'avanguardia della ricerca medica. La conferenza offre un'opportunità a Climb Bio di mostrare i propri sviluppi e interagire con investitori interessati ai progressi nel trattamento delle malattie autoimmuni.
Climb Bio (Nasdaq: CLYM) ha anunciado su participación en el evento Transforming Autoimmune Diseases by Targeting CD19 de William Blair. La compañía presentará y realizará reuniones con inversores en esta conferencia, que se llevará a cabo el miércoles 16 de octubre de 2024 en Nueva York, NY.
Este evento se centra en enfoques innovadores para tratar enfermedades autoinmunes, específicamente apuntando al CD19. La participación de Climb Bio sugiere que su trabajo está alineado con esta área de investigación médica de vanguardia. La conferencia brinda a Climb Bio la oportunidad de mostrar sus desarrollos e interactuar con inversores interesados en avances en el tratamiento de enfermedades autoinmunes.
Climb Bio (Nasdaq: CLYM)은 William Blair의 CD19를 표적으로 하는 자가면역 질환의 혁신적 변모 행사에 참여한다고 발표했습니다. 이 회사는 이번 컨퍼런스에서 발표 및 투자자 회의를 개최할 예정이며, 2024년 10월 16일 수요일에 뉴욕, NY에서 열립니다.
이 행사는 자가면역 질환 치료를 위한 혁신적인 접근 방식에 초점을 맞추고 있으며, 특히 CD19를 목표로 합니다. Climb Bio의 참여는 그들의 작업이 이 최첨단 의학 연구 분야와 일치함을 시사합니다. 이번 컨퍼런스는 Climb Bio가 자신의 발전을 선보이고 자가면역 질환 치료의 발전에 관심 있는 투자자들과 연결할 수 있는 기회를 제공합니다.
Climb Bio (Nasdaq: CLYM) a annoncé sa participation à l'événement Transforming Autoimmune Diseases by Targeting CD19 de William Blair. L'entreprise présentera et animera des réunions avec des investisseurs lors de cette conférence, prévue pour le mercredi 16 octobre 2024, à New York, NY.
Cette manifestation met l'accent sur des approches innovantes pour le traitement des maladies auto-immunes, en ciblant spécifiquement CD19. L'implication de Climb Bio suggère que leurs travaux s'inscrivent dans ce domaine de recherche médicale à la pointe. La conférence offre à Climb Bio l'opportunité de mettre en avant ses développements et d'interagir avec des investisseurs intéressés à faire avancer le traitement des maladies auto-immunes.
Climb Bio (Nasdaq: CLYM) hat seine Teilnahme an der Veranstaltung Transforming Autoimmune Diseases by Targeting CD19 von William Blair bekannt gegeben. Das Unternehmen wird bei dieser Konferenz, die für Mittwoch, den 16. Oktober 2024 in New York, NY geplant ist, Präsentationen halten und Investorenmeetings veranstalten.
Diese Veranstaltung konzentriert sich auf innovative Ansätze zur Behandlung von Autoimmunerkrankungen, insbesondere mit dem Ziel CD19. Die Beteiligung von Climb Bio deutet darauf hin, dass ihre Arbeit mit diesem fortschrittlichen Bereich der medizinischen Forschung übereinstimmt. Die Konferenz bietet Climb Bio die Möglichkeit, ihre Entwicklungen zu präsentieren und mit Investoren in Kontakt zu treten, die an Fortschritten in der Behandlung von Autoimmunerkrankungen interessiert sind.
- None.
- None.
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.
About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843
Media
Jon Yu
ICR Westwicke
jon.yu@westwicke.com
475-395-5375
FAQ
When and where is Climb Bio (CLYM) presenting at the William Blair conference?
What is the focus of the William Blair conference that Climb Bio (CLYM) is attending?
Will Climb Bio (CLYM) be hosting investor meetings at the William Blair event?
What does Climb Bio's (CLYM) participation in this conference suggest about their research focus?
